It was subsequently evaluated in thenonmetastatic setting and showed striking benefits in relapse-free survival and overall survival (OS), leading to itsapproved use in patients with early-stage HER2-positive breast cancer in 2006 (Romond et al., 2005; Piccart-Gebhart,2005). Here, ERBB2 is linked to breast carcinoma.